|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM167341162 |
| 003 |
DE-627 |
| 005 |
20240415231907.0 |
| 007 |
tu |
| 008 |
231223s2007 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n1375.xml
|
| 035 |
|
|
|a (DE-627)NLM167341162
|
| 035 |
|
|
|a (NLM)17185040
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lombard, Catherine
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells
|b potential role for CB2-selective ligands as immunosuppressive agents
|
| 264 |
|
1 |
|c 2007
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.04.2007
|
| 500 |
|
|
|a Date Revised 14.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Cannabinoids are known to interact with CB1 and CB2 receptors expressed in the nervous and immune system, respectively, and mediate a wide range of effects, including anti-inflammatory properties. However, cannabinoids that bind CB1 are also psychoactive thereby limiting their clinical use. In this study, we investigated the immunosuppressive properties of JWH-015, a synthetic CB2-selective agonist. We found that JWH-015 triggered apoptosis in thymocytes in vitro and inhibited the proliferative response of T and B cells to mitogens through induction of apoptosis. JWH-015 induced cross-talk between extrinsic and intrinsic pathways of apoptosis involving caspase-8, caspase-9, and caspase-3 as well as loss of mitochondrial membrane potential. Finally, administration of JWH-015 in vivo caused thymic atrophy, apoptosis, and decreased peripheral T cell response to mitogens. Together, this study suggests that CB2-selective agonists, devoid of psychotropic effect, may serve as novel anti-inflammatory/immunosuppressive agents
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
7 |
|a Growth Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Indoles
|2 NLM
|
| 650 |
|
7 |
|a Ligands
|2 NLM
|
| 650 |
|
7 |
|a Mitogens
|2 NLM
|
| 650 |
|
7 |
|a Receptor, Cannabinoid, CB2
|2 NLM
|
| 650 |
|
7 |
|a JHW 015
|2 NLM
|
| 650 |
|
7 |
|a W4FL204T10
|2 NLM
|
| 700 |
1 |
|
|a Nagarkatti, Mitzi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nagarkatti, Prakash
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 122(2007), 3 vom: 01. März, Seite 259-70
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:122
|g year:2007
|g number:3
|g day:01
|g month:03
|g pages:259-70
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 122
|j 2007
|e 3
|b 01
|c 03
|h 259-70
|